New launch milestone, Stelara biosimilar Wezlana reshapes J&J’s immunology lineup

With Wezlana, Johnson & Johnson brings the first FDA-approved Stelara biosimilar to market, targeting plaque psoriasis and psoriatic arthritis with a lower list price and a key role in the group’s high-margin immunology portfolio.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 3:00 AM ET. Details in the imprint.

Johnson & Johnson is highlighting its latest US launch in immunology: Wezlana, a Stelara biosimilar developed with Alvotech, is now available in the United States for adults with moderate to severe plaque psoriasis and active psoriatic arthritis. The product, which references J&J’s own blockbuster Stelara (ustekinumab), enters the market as one of the first interchangeable ustekinumab biosimilars with a list price reportedly below the originator’s, positioning it as a key test case for how fast specialty-drug biosimilars can gain traction in dermatology and rheumatology. According to J&J’s official launch statement, Wezlana became commercially available in the US after securing FDA approval as an interchangeable biosimilar to Stelara for all approved indications of the reference product.

What Wezlana does and how it aligns with Stelara

Wezlana contains ustekinumab, a monoclonal antibody targeting interleukins 12 and 23, and is approved as a biosimilar to Stelara for adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, as well as for adults with active psoriatic arthritis, mirroring the reference product’s core immunology indications. The drug is supplied as a subcutaneous injection in prefilled syringes, with dosing regimens aligned to weight-based schedules similar to Stelara, enabling physicians already familiar with ustekinumab to transition appropriate patients without having to relearn dosing algorithms or monitoring routines. Wezlana’s interchangeable status under US law means that, subject to state pharmacy regulations, pharmacists in many jurisdictions can substitute it for Stelara at the pharmacy level for eligible prescriptions, a mechanism that historically accelerated uptake in other biologic classes such as insulin and anti-TNF therapies.

For patients and payers, the central differentiator is price: J&J has positioned Wezlana with a list price discount versus Stelara, while at the same time negotiating formulary status with large US pharmacy benefit managers (PBMs) and health insurers to secure preferred placement that can drive volume. Industry analysts expect that even modest percentage discounts in the high-cost specialty biologic segment can translate into substantial absolute savings for health plans and government programs such as Medicare and Medicaid, given that annual therapy costs for originator ustekinumab therapy have commonly run into the tens of thousands of dollars per patient before discounts and rebates, creating strong economic incentives for plan sponsors to shift stable patients to biosimilars when clinically appropriate. Coverage in FiercePharma underscores that payers are already steering utilization toward Wezlana and other ustekinumab biosimilars via step therapy and preferred tiers, which could gradually erode Stelara’s market share while broadening patient access.

Strategically, Wezlana sits in an unusual position within Johnson & Johnson’s portfolio because it is a biosimilar to the group’s own high-revenue originator, effectively allowing the company to defend share in ustekinumab while still participating in the inevitable price competition. The immunology franchise has long been a central profit driver for J&J, and maintaining strong positions in inflammatory diseases is critical as older biologics face patent expiry and new competitors, including IL-23-only antibodies and JAK inhibitors, crowd into dermatology and rheumatology treatment algorithms. By co-developing and commercializing an interchangeable biosimilar with Alvotech, J&J aims not only to keep a foothold in the ustekinumab segment but also to demonstrate to regulators and prescribers that it can manage biologic life cycles across both originator and biosimilar strategies, potentially applying similar approaches to other molecules as exclusivity windows close in coming years.

In terms of clinical practice, Wezlana’s real-world uptake will hinge on dermatologists’ and rheumatologists’ comfort with biosimilar substitution in chronic immune-mediated diseases where long-term disease control and patient confidence are central. Many physicians are already familiar with biosimilars in anti-TNF therapies such as infliximab and adalimumab, where safety and efficacy data have accumulated over several years, reducing initial reservations and supporting broader use in everyday practice. The availability of an interchangeable ustekinumab biosimilar may extend that comfort to IL-12/23-targeted therapy, especially as more comparative and switching data are published, but prescriber habits, patient concerns about switching from a therapy that has kept disease stable and the specifics of insurance coverage will likely determine how quickly Wezlana displaces Stelara in established treatment regimens.

For Johnson & Johnson, the commercial trajectory of Wezlana will likely be watched closely by both healthcare investors and policymakers as a real-time case study in how deeply biosimilars can penetrate biologic markets when the originator manufacturer also participates in the biosimilar segment. The company has stated that its broader strategy includes balancing continued innovation in next-generation immunology drugs with disciplined life-cycle management of existing brands, and Wezlana provides a concrete example of that balancing act as Stelara’s US exclusivity period winds down. Shares of Johnson & Johnson (ISIN US4781601046) traded on the NYSE at around $145 on 06/14/2026, reflecting a diversified healthcare portfolio where immunology remains a significant earnings contributor but is increasingly complemented by medical technology and innovative medicines growth. Recent NYSE data for J&J’s listing provide the latest trading range and market capitalization context for the group.

Wezlana quick profile: key facts at a glance

• Product: Wezlana (ustekinumab-auub)
• Manufacturer: Johnson & Johnson
• Category: New Release/Launch - immunology biosimilar
• Launch date: Commercial availability in the US following FDA approval as an interchangeable Stelara biosimilar
• MSRP / Price: List price positioned below reference Stelara; exact net cost depends on payer contracts and rebates
• Availability: Prescription-only in the United States for adult plaque psoriasis and psoriatic arthritis via specialty pharmacies and hospital channels
• Target audience: Adult patients with moderate to severe plaque psoriasis or active psoriatic arthritis eligible for systemic biologic therapy, as well as US payers seeking lower-cost ustekinumab options
• Key differentiator / USP: First FDA-approved interchangeable biosimilar referencing J&J’s own Stelara, combining originator-level experience with biosimilar pricing dynamics

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.